PROCEPT BioRobotics (PRCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting will be held virtually on June 9, 2026, with shareholders voting on director elections, auditor ratification, and executive compensation approval.
Only shareholders of record as of April 10, 2026, are eligible to vote, with detailed instructions for both record and beneficial holders.
The company emphasizes virtual meetings for broader access, cost savings, and environmental benefits.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class II directors (Antal Desai, Mary Garrett, Frederic Moll, M.D.) for terms expiring in 2029.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026 is on the agenda.
A non-binding advisory vote on executive compensation (say-on-pay) is included.
Board recommends voting FOR all proposals.
Procedures for submitting shareholder proposals and nominations for the 2027 meeting are detailed, with deadlines and requirements.
Board of directors and corporate governance
The board consists of nine members divided into three staggered classes, with a majority deemed independent under Nasdaq standards.
Chair and CEO roles are separated to reinforce board independence.
Board committees include Audit, Compensation, and Nominating & ESG, all composed of independent directors.
Directors are encouraged to attend annual meetings; board and committee attendance exceeded 75% in 2025.
Stock ownership policy requires directors to hold shares valued at five times their base annual retainer.
Latest events from PROCEPT BioRobotics
- Q1 revenue up 20% to $83.1M, gross margin 65%, with strong U.S. and international growth.PRCT
Q1 202629 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay on June 9, 2026.PRCT
Proxy filing23 Apr 2026 - Launch teams, inventory optimization, and HYDROS upgrades set the stage for growth in 2024–2026.PRCT
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Strong growth, margin expansion, and innovation drive leadership in BPH and new cancer markets.PRCT
Investor Day 202626 Feb 2026 - Q4 saw record procedures and 12% revenue growth, with 2026 guidance targeting 27%–33% growth.PRCT
Q4 202526 Feb 2026 - Improved visibility, rising utilization, and new clinical studies drive strong growth and margin expansion.PRCT
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 revenue up 61% to $53.4M, gross margin at 59%, FY24 guidance raised to $217M.PRCT
Q2 20242 Feb 2026 - FDA clears next-gen AI robotic system, reaffirming 2024 guidance and enabling broad US rollout.PRCT
Status Update1 Feb 2026 - Strong clinical results and expanding adoption drive growth, with new cancer studies underway.PRCT
The 44th Annual William Blair Growth Stock Conference31 Jan 2026